A citation-based method for searching scientific literature

Ralph P Tufano, Gilberto V Teixeira, Justin Bishop, Kathryn A Carson, Mingzhao Xing. Medicine (Baltimore) 2012
Times Cited: 194







List of co-cited articles
1035 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
54

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, David Viola, Rossella Elisei, Bela Bendlova, Linwah Yip, Caterina Mian, Federica Vianello, R Michael Tuttle,[...]. JAMA 2013
533
46

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Mingzhao Xing, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A Zeiger, Sara Pai, Justin Bishop. J Clin Oncol 2014
379
31

The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.
Tae Hyuk Kim, Young Joo Park, Jung Ah Lim, Hwa Young Ahn, Eun Kyung Lee, You Jin Lee, Kyung Won Kim, Seo Kyung Hahn, Yeo Kyu Youn, Kwang Hyun Kim,[...]. Cancer 2012
284
31


BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
Mingzhao Xing, William H Westra, Ralph P Tufano, Yoram Cohen, Eli Rosenbaum, Kerry J Rhoden, Kathryn A Carson, Vasily Vasko, Alexandr Larin, Giovanni Tallini,[...]. J Clin Endocrinol Metab 2005
683
27

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei, Bela Bendlová, Linwah Yip, Caterina Mian,[...]. J Clin Oncol 2015
290
27


BRAF mutation in thyroid cancer.
M Xing. Endocr Relat Cancer 2005
878
24

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Miguel Melo, Adriana Gaspar da Rocha, João Vinagre, Rui Batista, Joana Peixoto, Catarina Tavares, Ricardo Celestino, Ana Almeida, Catarina Salgado, Catarina Eloy,[...]. J Clin Endocrinol Metab 2014
299
23

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
David S Cooper, Gerard M Doherty, Bryan R Haugen, Richard T Kloos, Stephanie L Lee, Susan J Mandel, Ernest L Mazzaferri, Bryan McIver, Furio Pacini, Martin Schlumberger,[...]. Thyroid 2009
21

BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.
Carol Li, Kathleen C Lee, Eric B Schneider, Martha A Zeiger. J Clin Endocrinol Metab 2012
160
21

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Xiaoli Liu, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K El-Naggar, Mingzhao Xing. Endocr Relat Cancer 2013
357
20

Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Christopher Gouveia, Nhu Thuy Can, Alan Bostrom, James P Grenert, Annemieke van Zante, Lisa A Orloff. JAMA Otolaryngol Head Neck Surg 2013
70
24

TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Xiaoli Liu, Shen Qu, Rengyun Liu, Chunjun Sheng, Xiaoguang Shi, Guangwu Zhu, Avaniyapuram Kannan Murugan, Haixia Guan, Hongyu Yu, Yangang Wang,[...]. J Clin Endocrinol Metab 2014
180
16

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
16

TERT promoter mutations in thyroid cancer.
Rengyun Liu, Mingzhao Xing. Endocr Relat Cancer 2016
178
16

Molecular genetics and diagnosis of thyroid cancer.
Yuri E Nikiforov, Marina N Nikiforova. Nat Rev Endocrinol 2011
557
15


BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.
Marina N Nikiforova, Edna T Kimura, Manoj Gandhi, Paul W Biddinger, Jeffrey A Knauf, Fulvio Basolo, Zhaowen Zhu, Riccardo Giannini, Giuliana Salvatore, Alfredo Fusco,[...]. J Clin Endocrinol Metab 2003
740
14

Progress in molecular-based management of differentiated thyroid cancer.
Mingzhao Xing, Bryan R Haugen, Martin Schlumberger. Lancet 2013
322
14


BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.
Yasuhiro Ito, Hiroshi Yoshida, Rie Maruo, Shinji Morita, Toru Takano, Mitsuyoshi Hirokawa, Tomonori Yabuta, Mitsuhiro Fukushima, Hiroyuki Inoue, Chisato Tomoda,[...]. Endocr J 2009
184
14

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Rossella Elisei, Clara Ugolini, David Viola, Cristiana Lupi, Agnese Biagini, Riccardo Giannini, Cristina Romei, Paolo Miccoli, Aldo Pinchera, Fulvio Basolo. J Clin Endocrinol Metab 2008
354
14


The prevalence and prognostic value of BRAF mutation in thyroid cancer.
Electron Kebebew, Julie Weng, Juergen Bauer, Gustavo Ranvier, Orlo H Clark, Quan-Yang Duh, Daniel Shibru, Boris Bastian, Ann Griffin. Ann Surg 2007
311
13

Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.
Gabriella Pellegriti, Francesco Frasca, Concetto Regalbuto, Sebastiano Squatrito, Riccardo Vigneri. J Cancer Epidemiol 2013
649
13

The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
Rossella Elisei, David Viola, Liborio Torregrossa, Riccardo Giannini, Cristina Romei, Clara Ugolini, Eleonora Molinaro, Laura Agate, Agnese Biagini, Cristiana Lupi,[...]. J Clin Endocrinol Metab 2012
165
12

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
Iñigo Landa, Ian Ganly, Timothy A Chan, Norisato Mitsutake, Michiko Matsuse, Tihana Ibrahimpasic, Ronald A Ghossein, James A Fagin. J Clin Endocrinol Metab 2013
254
12

The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension.
Gregory W Randolph, Quan-Yang Duh, Keith S Heller, Virginia A LiVolsi, Susan J Mandel, David L Steward, Ralph P Tufano, R Michael Tuttle. Thyroid 2012
395
12

Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples.
Yuri E Nikiforov, N Paul Ohori, Steven P Hodak, Sally E Carty, Shane O LeBeau, Robert L Ferris, Linwah Yip, Raja R Seethala, Mitchell E Tublin, Michael T Stang,[...]. J Clin Endocrinol Metab 2011
493
11

Current thyroid cancer trends in the United States.
Louise Davies, H Gilbert Welch. JAMA Otolaryngol Head Neck Surg 2014
858
11


BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
Su-jin Kim, Kyu Eun Lee, Jun Pyo Myong, Jeong-hwan Park, Yoon Kyung Jeon, Hye Sook Min, So Yeon Park, Kyeong Cheon Jung, Do Hoon Koo, Yeo-Kyu Youn. World J Surg 2012
107
11


Effects of Coexistent BRAFV600E and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis.
Shinje Moon, Young Shin Song, Ye An Kim, Jung Ah Lim, Sun Wook Cho, Jae Hoon Moon, Seokyung Hahn, Do Joon Park, Young Joo Park. Thyroid 2017
66
16

Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
L Fugazzola, E Puxeddu, N Avenia, C Romei, V Cirello, A Cavaliere, P Faviana, D Mannavola, S Moretti, S Rossi,[...]. Endocr Relat Cancer 2006
184
10


The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Tae Yong Kim, Won Bae Kim, Yoon Soo Rhee, Ja Young Song, Jung Min Kim, Gyungyub Gong, Seungkoo Lee, Sang Yoon Kim, Seong Chul Kim, Suck Joon Hong,[...]. Clin Endocrinol (Oxf) 2006
191
10

Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Young Shin Song, Jung Ah Lim, Hoonsung Choi, Jae-Kyung Won, Jae Hoon Moon, Sun Wook Cho, Kyu Eun Lee, Young Joo Park, Ka Hee Yi, Do Joon Park,[...]. Cancer 2016
87
11

TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
Greta Gandolfi, Moira Ragazzi, Andrea Frasoldati, Simonetta Piana, Alessia Ciarrocchi, Valentina Sancisi. Eur J Endocrinol 2015
77
12

Frequency of TERT promoter mutations in human cancers.
João Vinagre, Ana Almeida, Helena Pópulo, Rui Batista, Joana Lyra, Vasco Pinto, Ricardo Coelho, Ricardo Celestino, Hugo Prazeres, Luis Lima,[...]. Nat Commun 2013
512
10

Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
Linwah Yip, Marina N Nikiforova, Jenny Y Yoo, Kelly L McCoy, Michael T Stang, Michaele J Armstrong, Kristina J Nicholson, N Paul Ohori, Christopher Coyne, Steven P Hodak,[...]. Ann Surg 2015
59
16

Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.
Cristiana Lupi, Riccardo Giannini, Clara Ugolini, Agnese Proietti, Piero Berti, Michele Minuto, Gabriele Materazzi, Rossella Elisei, Massimo Santoro, Paolo Miccoli,[...]. J Clin Endocrinol Metab 2007
293
9

Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center.
Jae Yun Lim, Soon Won Hong, Yong Sang Lee, Bup-Woo Kim, Cheong Soo Park, Hang-Seok Chang, Jae Yong Cho. Thyroid 2013
73
12

The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma.
Kuai-Lu Lin, Ou-Chen Wang, Xiao-Hua Zhang, Xuan-Xuan Dai, Xiao-Qu Hu, Jin-Miao Qu. Ann Surg Oncol 2010
117
9

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Julio C Ricarte-Filho, Mabel Ryder, Dhananjay A Chitale, Michael Rivera, Adriana Heguy, Marc Ladanyi, Manickam Janakiraman, David Solit, Jeffrey A Knauf, R Michael Tuttle,[...]. Cancer Res 2009
349
9

Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.
Yuri E Nikiforov, Sally E Carty, Simon I Chiosea, Christopher Coyne, Umamaheswar Duvvuri, Robert L Ferris, William E Gooding, Steven P Hodak, Shane O LeBeau, N Paul Ohori,[...]. Cancer 2014
300
9

Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.
Erik K Alexander, Giulia C Kennedy, Zubair W Baloch, Edmund S Cibas, Darya Chudova, James Diggans, Lyssa Friedman, Richard T Kloos, Virginia A LiVolsi, Susan J Mandel,[...]. N Engl J Med 2012
663
9

Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases.
Xiangqian Zheng, Songfeng Wei, Ying Han, Yancong Li, Yang Yu, Xinwei Yun, Xiubao Ren, Ming Gao. Ann Surg Oncol 2013
71
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.